192 related articles for article (PubMed ID: 34980710)
1. Antiviral Susceptibilities of Avian Influenza A(H5), A(H7), and A(H9) Viruses Isolated in Japan.
Takashita E; Morita H; Nagata S; Shirakura M; Fujisaki S; Miura H; Takayama I; Arita T; Suzuki Y; Yamaoka M; Tanikawa T; Tsunekuni R; Mine J; Sakuma S; Uchida Y; Shibata A; Iwanaka M; Kishida N; Nakamura K; Kageyama T; Watanabe S; Hasegawa H;
Jpn J Infect Dis; 2022 Jul; 75(4):398-402. PubMed ID: 34980710
[TBL] [Abstract][Full Text] [Related]
2. Antiviral susceptibility of highly pathogenic avian influenza A(H5N1) viruses isolated from poultry, Vietnam, 2009-2011.
Nguyen HT; Nguyen T; Mishin VP; Sleeman K; Balish A; Jones J; Creanga A; Marjuki H; Uyeki TM; Nguyen DH; Nguyen DT; Do HT; Klimov AI; Davis CT; Gubareva LV
Emerg Infect Dis; 2013 Dec; 19(12):1963-71. PubMed ID: 24274711
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the neuraminidase of subtype H5N1 avian influenza A viruses.
Takano R; Kiso M; Igarashi M; Le QM; Sekijima M; Ito K; Takada A; Kawaoka Y
J Infect Dis; 2013 Jan; 207(1):89-97. PubMed ID: 23053629
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
Hurt AC; Selleck P; Komadina N; Shaw R; Brown L; Barr IG
Antiviral Res; 2007 Mar; 73(3):228-31. PubMed ID: 17112602
[TBL] [Abstract][Full Text] [Related]
5. Functional neuraminidase inhibitor resistance motifs in avian influenza A(H5Nx) viruses.
Bialy D; Shelton H
Antiviral Res; 2020 Oct; 182():104886. PubMed ID: 32750468
[TBL] [Abstract][Full Text] [Related]
6. Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts.
Tang J; Zhang J; Zhou J; Zhu W; Yang L; Zou S; Wei H; Xin L; Huang W; Li X; Cheng Y; Wang D
Virol J; 2019 Jul; 16(1):87. PubMed ID: 31266524
[TBL] [Abstract][Full Text] [Related]
7. Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.
Stoner TD; Krauss S; DuBois RM; Negovetich NJ; Stallknecht DE; Senne DA; Gramer MR; Swafford S; DeLiberto T; Govorkova EA; Webster RG
J Virol; 2010 Oct; 84(19):9800-9. PubMed ID: 20660186
[TBL] [Abstract][Full Text] [Related]
8. Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
Farrukee R; Butler J; Reading PC; Hurt AC
Antiviral Res; 2019 Aug; 168():68-75. PubMed ID: 31132385
[TBL] [Abstract][Full Text] [Related]
9. Profile and generation of reduced neuraminidase inhibitor susceptibility in highly pathogenic avian influenza H7N9 virus from human cases in Mainland of China, 2016-2019.
Tang J; Zhang SX; Zhang J; Li XY; Zhou JF; Zou SM; Bo H; Xin L; Yang L; Liu J; Huang WJ; Dong J; Wang DY
Virology; 2020 Oct; 549():77-84. PubMed ID: 32853849
[TBL] [Abstract][Full Text] [Related]
10. Neuraminidase inhibitors and their role in avian and pandemic influenza.
Crusat M; de Jong MD
Antivir Ther; 2007; 12(4 Pt B):593-602. PubMed ID: 17944267
[TBL] [Abstract][Full Text] [Related]
11. Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022.
Nguyen HT; Chesnokov A; De La Cruz J; Pascua PNQ; Mishin VP; Jang Y; Jones J; Di H; Ivashchenko AA; Killian ML; Torchetti MK; Lantz K; Wentworth DE; Davis CT; Ivachtchenko AV; Gubareva LV
Antiviral Res; 2023 Sep; 217():105679. PubMed ID: 37494978
[TBL] [Abstract][Full Text] [Related]
12. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
Ikematsu H; Kawai N
Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
[TBL] [Abstract][Full Text] [Related]
13. Outbreak of highly pathogenic avian influenza in Japan and anti-influenza virus activity of povidone-iodine products.
Ito H; Ito T; Hikida M; Yashiro J; Otsuka A; Kida H; Otsuki K
Dermatology; 2006; 212 Suppl 1():115-8. PubMed ID: 16490988
[TBL] [Abstract][Full Text] [Related]
14. Neuraminidase inhibitors susceptibility profiles of highly pathogenic influenza A (H5N1) viruses isolated from avian species in India (2006-2015).
Sood R; Kumar N; Bhatia S; Chanu KV; Gupta CL; Pateriya AK; Mishra A; Khandia R; Mawale N; Singh VP
Antiviral Res; 2018 Oct; 158():143-146. PubMed ID: 30125616
[TBL] [Abstract][Full Text] [Related]
15. R292K substitution and drug susceptibility of influenza A(H7N9) viruses.
Sleeman K; Guo Z; Barnes J; Shaw M; Stevens J; Gubareva LV
Emerg Infect Dis; 2013; 19(9):1521-4. PubMed ID: 23965618
[TBL] [Abstract][Full Text] [Related]
16. Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.
Choi WS; Jeong JH; Kwon JJ; Ahn SJ; Lloren KKS; Kwon HI; Chae HB; Hwang J; Kim MH; Kim CJ; Webby RJ; Govorkova EA; Choi YK; Baek YH; Song MS
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046464
[TBL] [Abstract][Full Text] [Related]
17. Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses.
Ilyushina NA; Govorkova EA; Gray TE; Bovin NV; Webster RG
PLoS Pathog; 2008 Apr; 4(4):e1000043. PubMed ID: 18404209
[TBL] [Abstract][Full Text] [Related]
18. Antiviral Susceptibility of Highly Pathogenic Avian Influenza A(H5N1) Viruses Circulating Globally in 2022-2023.
Andreev K; Jones JC; Seiler P; Kandeil A; Turner JCM; Barman S; Rubrum AM; Webby RJ; Govorkova EA
J Infect Dis; 2024 Jun; 229(6):1830-1835. PubMed ID: 37770028
[TBL] [Abstract][Full Text] [Related]
19. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020.
Govorkova EA; Takashita E; Daniels RS; Fujisaki S; Presser LD; Patel MC; Huang W; Lackenby A; Nguyen HT; Pereyaslov D; Rattigan A; Brown SK; Samaan M; Subbarao K; Wong S; Wang D; Webby RJ; Yen HL; Zhang W; Meijer A; Gubareva LV
Antiviral Res; 2022 Apr; 200():105281. PubMed ID: 35292289
[TBL] [Abstract][Full Text] [Related]
20. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
Takashita E; Daniels RS; Fujisaki S; Gregory V; Gubareva LV; Huang W; Hurt AC; Lackenby A; Nguyen HT; Pereyaslov D; Roe M; Samaan M; Subbarao K; Tse H; Wang D; Yen HL; Zhang W; Meijer A
Antiviral Res; 2020 Mar; 175():104718. PubMed ID: 32004620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
